SCHEMBL1127424

SCHEMBL1127424

CCOC(=O)C(Cc1ccccc1)c1ccccn1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.57
KMT2A Q03164 2/20 0.57
SMN1; SMN2 Q16637 2/20 0.57
GAA P10253 1/20 0.57
ALDH1A1 P00352 2/20 0.53
KDM4E B2RXH2 2/20 0.53
GPR119 Q8TDV5 2/20 0.52
PKM P14618 1/20 0.50
MMP8 P22894 1/20 0.49
CYP1A2 P05177 2/20 0.47
EPHX2 P34913 1/20 0.44
PPARG P37231 1/20 0.44
PSMB5 P28074 1/20 0.44
CHRM1 P11229 1/20 0.44
NPC1 O15118 1/20 0.43
LMNA P02545 3/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
TSHR P16473 2/20 0.42
CYP2C19 P33261 1/20 0.42
CYP2D6 P10635 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1127316 0.89 MEN1 (0.52) MEN1KMT2ASMN1; SMN2GAAALDH1A1
SCHEMBL1127707 0.89 KMT2A (0.52) MEN1KMT2ASMN1; SMN2GAAALDH1A1
SCHEMBL25215975 0.87 PSMB5 (0.48) MEN1KMT2ASMN1; SMN2GAAALDH1A1
SCHEMBL1127447 0.86 KMT2A (0.49) MEN1KMT2ASMN1; SMN2GAAALDH1A1
SCHEMBL1127873 0.86 MEN1 (0.49) MEN1KMT2ASMN1; SMN2GAAALDH1A1
SCHEMBL11532666 0.86 MEN1 (0.57) MEN1KMT2ASMN1; SMN2GAAALDH1A1
SCHEMBL1127494 0.85 KMT2A (0.51) MEN1KMT2ASMN1; SMN2GAAALDH1A1
SCHEMBL27140633 0.85 ALDH1A1 (0.55) MEN1KMT2ASMN1; SMN2GAAALDH1A1
SCHEMBL1127513 0.84 KMT2A (0.50) MEN1KMT2ASMN1; SMN2GAAALDH1A1
SCHEMBL10869559 0.84 SMN1; SMN2 (0.52) MEN1KMT2ASMN1; SMN2GAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2283002-A2 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION Intermune, Inc. (US) 2011-02-16 EP disclosed
WO-2009134616-A2 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2009-11-05 WO disclosed
WO-2009134616-A2 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2009-11-05 WO disclosed
US-20090257979-A1 Novel Inhibitors of Hepatitis C Virus Replication INTERMUNE, INC. (US) 2009-10-15 US disclosed
US-20090257979-A1 Novel Inhibitors of Hepatitis C Virus Replication INTERMUNE, INC. (US) 2009-10-15 US disclosed
US-20090257979-A1 Novel Inhibitors of Hepatitis C Virus Replication INTERMUNE, INC. (US) 2009-10-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090257979-A1 Novel Inhibitors of Hepatitis C Virus Replication EIF2AK2, HAVCR2, HDGF MEN1 4723/4885KMT2A 2735/4885SMN1; SMN2 3563/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.